Title: High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients
Authors: van der Velden, VH ×
Boeckx, Nancy
Jedema, I
te Marvelde, JG
Hoogeveen, PG
Boogaerts, Marc
van Dongen, JJ #
Issue Date: May-2004
Publisher: Nature Publishing Group
Series Title: Leukemia vol:18 issue:5 pages:983-988
Abstract: Gemtuzumab ozogamicin (Mylotarg) induces remission in approximately 30% of relapsed AML patients. We previously demonstrated that gemtuzumab infusion results in near-complete CD33 saturation in peripheral blood, and that saturating gemtuzumab levels result in continuous binding and internalization of gemtuzumab due to renewed CD33 expression. We now demonstrate that a high CD33-antigen load in peripheral blood is an independent adverse prognostic factor, likely due to peripheral consumption of gemtuzumab. Indeed, CD33 saturation in bone marrow is significantly reduced (40-90% saturation) as compared with CD33 saturation in corresponding peripheral blood samples (>90%). In vitro, such reduced CD33 saturation levels were strongly related with reduced cell kill. Apparently, high CD33-antigen loads in blood consume gemtuzumab and thereby limit its penetration into bone marrow. Consequently, CD33 saturation in bone marrow is reduced, which hampers efficient cell kill. Therefore, gemtuzumab should be administered at higher or repeated doses, or, preferably, after reduction of the leukemic cell burden by classical chemotherapy.
ISSN: 0887-6924
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Hematology Section (-)
Laboratory of Clinical Bacteriology and Mycology
Department of Oncology - miscellaneous
× corresponding author
# (joint) last author

Files in This Item:
File Description Status SizeFormat
leukemia.pdf Published 184KbAdobe PDFView/Open


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science